Tesofensine Phase II obesity trial
Weight loss with tesofensine was 4.5%, 9.2% and 10.6% greater than the 2.0% placebo/diet response; authors called for Phase III confirmation.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with obesity
n=203
Weight loss with tesofensine was 4.5%, 9.2% and 10.6% greater than the 2.0% placebo/diet response; authors called for Phase III confirmation.
Older Phase II study; long-term cardiovascular benefit-risk and approval were not established by this trial.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Weight loss with tesofensine was 4.5%, 9.2% and 10.6% greater than the 2.0% placebo/diet response; authors called for Phase III confirmation.